February 1, 2012
FY2011 Full Year Consolidated Financial Overview
Financial Highlight
Consolidated Statements of Income
(millions of yen, amounts of less than one million yen are omitted)
| Revenues | Cost of sales | SG&A expenses | (R&D expenses) | Operating Income |
|---|---|---|---|---|
| 373,516 | 157,506 | 153,580 | 55,856 | 62,430 |
| Operating Income to Sales Ratio (%) | Ordinary income | Income before income taxes and minority interests | Net Income | Net Income per Share (Yen) |
|---|---|---|---|---|
| 16.7 | 63,585 | 57,131 | 35,234 | 64.75 |
Consolidated Balance Sheets
(millions of yen, amounts of less than one million yen are omitted)
| Total assets | Total current assets | Total noncurrent assets | Total current liabilities | Total noncurrent liabilities |
|---|---|---|---|---|
| 533,482 | 419,429 | 114,053 | 68,822 | 5,587 |
| Total shareholders' equity | Capital expenditure | Equity Ratio (%) | Annual dividend per share (yen) | Interim dividend per share (yen) |
|---|---|---|---|---|
| 468,998 | 11,927 | 85.6 | 40.00 | 20.00 |
Revenues and profits declined due to negative sales growth
Revenues: 373.5 billion JPY (-1.6%), Operating Income: 62.4 billion JPY (-5.7%)
Tamiflu® sales: significantly declined as stockpiling sales close out
Sales excl. Tamiflu®: slightly declined as the impact of the earthquake on domestic sales outweighed the growth in overseas sales
Other Operating Revenues: increased substantially from one-time events
Extraordinary Loss: 6.5 billion JPY
Loss on disaster: 4.7 billion JPY
Year-end dividend 20 JPY per share (40 JPY annual dividend), achieving a payout ratio of 61.8%
Jan-Dec 2011 Sales excluding Tamiflu®
Operating Income Jan-Dec
*Amounts are rounded to the nearest 0.1 billion yen.
Variance and % are calculated based on amounts shown.
Variance and % are calculated based on amounts shown.
More Information
- Supplementary Materials PDF [
152KB][Excel 167KB]
- Presentation [411KB]
- Webcasts
- Information Meeting on FY 2011.12 Financial Results [734KB]
To view PDF files,
you will need Adobe® Reader® which is available as a free download.
